Reprint

The Survival of Colon and Rectal Cancer

Edited by
August 2024
166 pages
  • ISBN978-3-7258-1679-8 (Hardback)
  • ISBN978-3-7258-1680-4 (PDF)
https://doi.org/10.3390/books978-3-7258-1680-4 (registering)

This book is a reprint of the Special Issue The Survival of Colon and Rectal Cancer that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Colorectal cancer is the third most common cancer in men and the second most common cancer in women. In 2020, there were more than 1.9 million new cases of colorectal cancer. With increasing life expectancy, we are seeing more elderly patients. However, the number of young patients under 50 is also increasing. Survival rates have improved by optimising surgical procedures such as total mesorectal excision (TME) and complete mesocolic excision (CME) and multidisciplinary approaches, especially for advanced carcinomas. In recent decades, standardisation of treatment has been an important tool for improving survival rates. Today, with increasing therapeutic options and the results of prognostic factor research, the possibilities to individualise therapy are increasing. Both under- and overtreatment should be avoided. Quality management is essential to improve outcomes. However, not only is the length of survival time important, but also the patient’s quality of life.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
N7-methylguanosine (m7G) methylation; m7G-related genes; colon cancer; prognostic model; colon carcinoma; pT3; T3 subdivision; distant metastasis; survival; prognosis; prognostic factor; TNM classification; rectal cancer; predictive factors; pre-operative treatment; pathologic complete remission; colon cancer; pathology; quality of surgery; feedback; macroscopic assessment; Enhanced Recovery After Surgery; rectal cancer; locally advanced rectal cancer; locally recurrent rectal cancer; surgery; certified cancer center; colon cancer; rectal cancer; cohort study; registries; survival; quality of cancer care; evidence-based medicine; WiZen; German Cancer Society; pelvic compartments; locally advanced rectal cancer; locally recurrent rectal cancer; MRI assessment; MRI-guided surgery; prognosis; PROs; rectal cancer; ostomy; sexual function; bladder function; quality of life; colon cancer; lymph nodes; lymph node yield; lymph node ratio; five-year overall survival; antiangiogenic treatment; cancer; colorectal cancer; endothelial cells; tumor microenvironment; bevacizumab; ramucirumab; aflibercept; regorafenib; fruquintinib; angiocrine; vasculature; vascular heterogeneity; rectal cancer; certification; colorectal cancer center; outcome